阅读说明：本技术 肺癌特异性tcr及其分析技术和应用 (Lung cancer specific TCR and analysis technology and application thereof ) 是由 张泽民 董明晖 郑良涛 张园园 郭心怡 胡学达 于 2018-06-25 设计创作，主要内容包括：本发明利用单细胞转录组分析技术,通过分析肺癌患者的癌症组织中浸润的T细胞的TCR基因,发现和分离并表征了一系列新的克隆性的TCR基因及其序列,这些TCR可能是由肿瘤细胞抗原刺激T细胞产生的,表达这些TCR的T细胞可能具有特异性识别肿瘤细胞抗原,并杀死肿瘤细胞的活性,存在用于过继细胞疗法的前景。(The invention utilizes a single cell transcriptome analysis technology, discovers, isolates and characterizes a series of new cloned TCR genes and sequences thereof by analyzing TCR genes of T cells infiltrated in cancer tissues of lung cancer patients, the TCRs can be generated by stimulating T cells by tumor cell antigens, the T cells expressing the TCRs can have the activities of specifically recognizing the tumor cell antigens and killing the tumor cells, and the invention has the prospect of being used for adoptive cell therapy.)

1. a TCR whose amino acid sequence of CDR3 of the α chain and amino acid sequence of CDR3 of the β chain are: SEQ ID No.1 and SEQ ID No.3 of Table 1, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.5 and SEQ ID No.7, respectively, of Table 2, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.9 and SEQ ID No.11 in Table 3, respectively, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.13 and SEQ ID No.15 in Table 4, respectively, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.17 and SEQ ID No.19, respectively, of Table 5, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.21 and SEQ ID No.23 in Table 6, respectively, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.25 and SEQ ID No.27 of Table 7, respectively, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.29 and SEQ ID No.31 in Table 8, respectively, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.33 and SEQ ID No.35, respectively, of Table 9, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.37 and SEQ ID No.39, respectively, of Table 10, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.41 and SEQ ID No.43, respectively, of Table 11, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.45 and SEQ ID No.47, respectively, of Table 12, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.49 and SEQ ID No.51 of Table 13, respectively, or sequences substantially similar thereto; or the like, or, alternatively,

SEQ ID No.53 and SEQ ID No.55, respectively, of Table 14, or sequences substantially similar thereto.

2. An isolated nucleic acid encoding the amino acid sequence of CDR3 of the α chain or the amino acid sequence of CDR3 of the β chain of the TCR of claim 1, or an amino acid sequence substantially similar to said amino acid sequence.

3. An expression vector comprising the nucleic acid of claim 2.

4. A host cell comprising the nucleic acid of claim 2.

5. A population of T cells, T cell lines or recombinantly expressed T cells having a TCR as claimed in claim 1 or encoding a nucleic acid sequence as claimed in claim 2.

6. A method of making a T cell comprising a TCR as claimed in claim 1 comprising the steps of: (1) determining the amino acid sequences of the candidate HLA and the test peptide based on the TCR of claim 1; (2) synthesizing the determined HLA and the test peptide and forming a complex in vitro; (3) stimulating lymphocytes with the HLA-peptide;

determining the amino acid sequence of the candidate HLA-peptide, preferably using a score calculated by an HLA-binding peptide prediction algorithm; preferably, the candidate HLA-peptide is determined using BIMAS, SYFPEITHI, RANKPEP or NetMHC.

7. A method of making a T cell comprising a TCR as claimed in claim 1 comprising the steps of: (1) introducing the TCR α or TCR β gene of claim 1 into a retroviral vector for gene expression; (2) creating a gene-introduced virus from a retroviral vector expressing TCR α and TCR β genes; (3) separately and sequentially infecting lymphocytes collected from a patient with the virus carrying the TCR α and TCR β genes to perform transfection, or creating a gene-expressing retroviral vector including the TCR α and TCR β genes to transform both genes at once; (4) it was demonstrated that the TCR α/TCR β heterodimer was expressed on the cell surface.

8. Use of the TCR of claim 1, the isolated nucleic acid of claim 2, the expression vector of claim 3, the host cell of claim 4, or the T cell population, T cell strain or recombinantly expressed T cell of claim 5 in the preparation of a medicament for the treatment of lung cancer.

9. A computational method for predicting the binding capacity of T cells in tumor tissue of a patient with lung cancer to TCR, MHC and small peptide fragments, comprising the steps of:

1) obtaining the RNA sequence of TCR of tumor immune cells of a lung cancer patient, the MHC type of the patient and the sequence of a small peptide segment, and inputting the sequences into RosettaDock software;

2) performing homologous modeling of the protein structure on the TCR sequence according to a database of known sequences and protein structures;

3) confirming 6 loop regions of CDR in TCR, carrying out step-by-step simulation, and calculating the binding free energy of the 6 loop regions; the confirmation method of the 6 loop regions comprises the steps of calculating the three-dimensional structure center of the small peptide segment according to the amino acid residues of the small peptide segment, identifying the loop regions of the CDR of the TCR according to RosettaDock software, calculating the distance between each loop region and the three-dimensional structure center of the small peptide segment, and selecting the 6 closest loop regions;

4) combining MHC, TCR and small peptide segments together, and respectively carrying out low-resolution and high-resolution docking process calculation to reach the maximum iteration times and terminate the calculation;

5) analyzing the result, RMSD, calculating the docking free energy and a scoring function value Rosetta score representing the strength of the binding capacity;

preferably, in step 1), the RNA sequence of TCR of tumor immune cells of cancer patients is obtained by a TCR analysis method of single-cell transcriptome of T cells;

preferably, in the step 1), the MHC type of the patient is obtained by adopting an exon sequencing method and operating optitype;

preferably, in the step 1), the small peptide fragment sequence in the body of the patient is predicted by adopting NetMHC and RNA sequencing technology;

preferably, in step 3), when step-by-step simulation is adopted, only one of 6 loop regions is released and the other 5 loop regions are fixed in each simulation.

10. A method for predicting or screening new lung cancer tumor antigens and/or screening TCRs from T cells in lung cancer tumor tissue, characterized in that the calculation method according to claim 9 is used to predict or screen the lower conformation of Rosetta score, the lower the energy state, the more likely it is a binding conformation that is actually present in the organism, the more likely it is that the small peptide fragments involved in the formation of this conformation are new antigens that elicit an immune response, and the more likely the corresponding TCR sequences are the most strongly binding TCRs, according to the scoring function Rosetta score obtained.

11. A method of screening for a TCR of a T cell or a lung cancer neoantigen in a lung cancer tumor tissue, the method comprising the steps of: 1) carrying out single cell transcriptome TCR analysis on T cells in lung cancer tumor tissues, and identifying to obtain TCR series and clonality identification of single T cells; 2) inputting the TCR obtained in the step 1), the MHC type of the tumor patient and the small peptide segment sequence into RosettaDock software, and calculating the binding capacity of the TCR, the MHC and the small peptide segment.

12. The method of claim 11, wherein: the step 1) further comprises the following steps: (a) obtaining individual T cells; (b) constructing a cDNA library of each T cell and sequencing to obtain the expression quantity of each gene of each cell; (c) identifying TCR sequences and clonal recognition of individual T cells;

preferably, a cDNA library of each T cell is constructed by using Smart-Seq2 and sequenced to obtain the expression level of each gene of each cell;

preferably, when the analysis of step (c) is performed, the bioinformatic data obtained in step (b) is compared and quality controlled, removing low quality parts; the method for controlling the data quality of sequencing reads (reads) of cDNA comprises the following steps: sequencing reads that met the following conditions were retained: firstly, unknown bases account for no more than 10 percent of the total sequence of a given read, secondly, bases with the Phred mass value lower than 5 do not exceed 50 percent, and thirdly, no linker sequence is contained; the method for controlling the cell quality is to remove the cells with low data quantity and data quality and keep the cells meeting the following conditions: the TPM of CD3D is larger than 3; ② when separating CD4⁺For T cells, the TPM of CD4 needs to be greater than 3, while the TPM of CD8 is less than 30; ③ separating CD8⁺For T cells, the TPM of CD8 needs to be greater than 3, while the TPM of CD4 is less than 30; the ratio of the reads on the mitochondrial gene to all reads is not higher than 10%, wherein the TPM value is defined as:

wherein C is_ijExpressed as the number of reads of gene i in cell j;

the quality control method for the gene expression quantity of the single cell for analysis comprises the following steps: the average number of reads detected for a gene in all cells is greater than 1 for subsequent analysis;

preferably, in step (c) the TCR sequence recognition of the individual T cells is performed using the software TraCeR, and in the clonal recognition, the following method is used: comparing sequences of TCR a and TCR β in any two cells, and when at least one TCR a and at least one TCR β sequence in the two cells are identical, the identical sequences of TCR a and TCR β are translated into effective proteins, and a TMP value of TCR a is at least greater than 10 and a TMP value of TCR β is at least greater than 15, such two cells are considered to be from the same clone.

13. The method of any of claims 11-12, wherein: step 2) further comprises the following steps: a) performing homologous modeling of the protein structure on the TCR sequence according to a database of known sequences and protein structures; b) calculating the three-dimensional structure center of the small peptide segment according to the amino acid residues of the small peptide segment, identifying the loop region of the CDR of the TCR according to RosettaDock software, calculating the distance between each loop region and the three-dimensional structure center of the small peptide segment, selecting 6 loop regions with the nearest distance, performing step-by-step simulation, and calculating the binding free energy of the 6 loop regions; c) combining MHC, TCR and small peptide segments together, and respectively carrying out low-resolution and high-resolution docking process calculation to reach the maximum iteration times and terminate the calculation; d) analyzing the result, RMSD, calculating the docking free energy and a scoring function value Rosetta score representing the strength of the binding capacity;

preferably, in step b), only 1 of the 6 loop regions is released and the remaining 5 are fixed during step simulation.

Technical Field

The invention relates to the field of biotechnology, in particular to a lung cancer specific TCR and an analysis technology thereof, and application of the lung cancer specific TCR in lung cancer treatment.

Background

Higher biological defense mechanisms are highly dependent on the adoptive immune system, including T cells and B cells. T cells have a specific receptor molecule, tcr (T cell receptor), expressed on the cell surface, which is able to recognize and distinguish self or foreign antigens. Intracellular signals are transmitted by antigen receptor reaction to promote cell proliferation, and further initiate various immune responses, such as enhancement of production of inflammatory cytokines, chemokines, and the like.

The TCR recognizes binding to the Major Histocompatibility Complex (MHC) expressed by antigen presenting cells and to antigenic peptides, forming a peptide-MHC (pmhc) -TCR complex, distinguishing self from non-self antigens and recognizing antigenic peptides. The TCR is a heterodimeric receptor molecule consisting of two TCR polypeptide chains, with most T cells expressing α β TCR and a few expressing γ δ TCR with a special function. The α and β chain TCR molecules form complexes with multiple CD3 molecules (CD3 ζ chain, CD3 ε chain, CD3 γ chain, and CD3 δ chain), transmit intracellular signals following antigen recognition, and initiate a variety of immune responses. Endogenous antigens, such as cancer antigens from cancer cells or viral antigens that proliferate within cells, are presented as antigenic peptides by MHC class I molecules. Antigen presenting cells obtain and process antigens derived from exogenous microorganisms by endocytosis, and then present on mhc class ii molecules. Such antigen is protected by CD8⁺T cells and CD4⁺TCR recognition expressed by each T cell.

The TCR gene consists of multiple V (variable, V), J (junction, J), D (diversity, D) and C (constant, C) regions encoded by different regions in the genome. These gene segments undergo gene rearrangement in various combinations during T cell differentiation. The α and γ chain TCRs express genes consisting of V-J-C, while the β and δ chain TCRs express genes consisting of V-D-J-C. Currently, the database of IMGT (International Immuno GeneTiCs project) has 43 functional α -chain TCR V

The region of direct binding of the TCR molecule to the surface of the pMHC complex (TCR footprint) is made up of three diverse Complementary Determining Region (CDR) CDR1, CDR2 and CDR3 regions within the V region. The CDR3 region specifically includes a portion of the V region, a portion of the J region, and a V-D-J region formed by random sequences, forming the most diverse antigen recognition site. Meanwhile, the other region is called FR (framework region) for forming the framework structure of the TCR molecule. During differentiation and maturation of T cells in the thymus, the β chain TCR undergoes gene rearrangement first, and is conjugated to the pT α molecule to form a pre-TCR complex molecule. The α chain TCR then rearranges to form an α β TCR molecule, and when a functional α β TCR is not formed, then rearrangement occurs in the other α chain TCR gene alleles. It is known that after positive/negative selection in the thymus, TCRs with appropriate affinity are selected for antigen specificity.

T cells produce a TCR with a high level of specificity for a particular antigen. Since there are many antigen-specific T cells in a living organism, diverse TCR repertoires can be formed to effectively act as defense mechanisms against a variety of pathogens, which are important indicators of the specificity or diversity of immune cells. Analysis of the TCR repertoire is a useful approach to enhance the efficacy of immune responses or to treat autoimmune diseases. If T cells proliferate in response to an antigen, an increased ratio of specific TCR genes (increased clonality) is observed in the diverse repertoire. Attempts have been made to detect the development of TCR-expressing lymphocytes in tumors by analyzing TCR repertoires for increases in clonality (Leukemia Research, 2003, 27, 305-); it has been reported that the frequency of use of a particular V β chain increases when exposed to a molecule that selectively stimulates a TCR with that particular V β chain, such as a superantigen (Immunology 1999, 96, 465-72.). In order to study antigen-specific immune responses, it is frequently used to analyze intractable autoimmune diseases induced by immune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, schungs syndrome, and characteristic thrombocytopenic purpura, and its usefulness has been demonstrated.

Immunotherapy has become an indispensable link in clinical treatment of tumors at present. The drugs and regimens for immunotherapy involve various stages of the body's immune system recognizing and attacking cancer cells. Existing tumor immunity drugs include several types: cancer cell-targeting antibodies, adoptive cell therapy, oncolytic viruses, dendritic cell-related therapy, tumor vaccines at DNA and protein levels, immune activating cytokines, and other immunomodulatory compounds. Among them, antibody drugs against T cell checkpoint inhibitory proteins and T cell adoptive therapies specific to tumor antigens have made a breakthrough in recent years and have attracted much attention.

Adoptive Cell Therapy (ACT) is the administration of activated T lymphocytes into the body for immune function. The general operation mode is as follows: isolating a tumor infiltrating lymphocyte population from the patient's tumor tissue, isolating T cells therefrom and culturing and activating in vitro with T cell growth factors (e.g., IL-2); screening out T cells with tumor specificity, carrying out in-vitro amplification culture, and then inputting into a patient for combined treatment with chemotherapy or radiotherapy. ACT the most challenging step is that T cells specifically recognize tumor cells. Chimeric Antigen Receptor-T cell (CAR-T) therapy and TCR-T therapy are effective approaches to improve their efficiency. CAR-T requires the construction of a chimeric antigen receptor, usually a variable region encoded by a gene encoding two antibody variable regions, which is then grafted onto the intracellular portion of the TCR, which can activate T cell immune activity. The TCR-T therapy uses human tumor antigen to stimulate mice expressing human MHC I, so as to obtain mouse T cells which specifically kill tumors, clone TCR of the mouse T cells and express the mouse T cells on T cells of patients, and finally, the modified cells are returned to the bodies of the patients for immunization therapy. Therefore, how to efficiently isolate and analyze patient-individualized TCRs and develop TCR-T cells that can be used for tumor therapy has important clinical value.

Disclosure of Invention

The present inventors have discovered, isolated and characterized a series of novel clonal TCR genes and their sequences by analyzing infiltrating T cells in cancer tissues of lung cancer patients using single cell transcriptome analysis techniques, the TCRs may be produced by stimulating T cells with tumor cell antigens, and the T cells expressing the TCRs may have activities of specifically recognizing tumor cell antigens and killing tumor cells, and thus have a prospect for adoptive cell therapy.

Furthermore, the present inventors provide a method for predicting the binding capacity of TCR, MHC and small peptide fragments by using single cell TCR sequences for flexible docking, and for predicting or discovering new tumor antigens in lung cancer patients.

It is an object of the present invention to provide a series of novel TCRs. It is a further object of the invention to provide nucleic acid sequences encoding these TCRs. It is another object of the invention to provide an expression vector carrying the nucleic acid sequence of the TCR. It is another object of the invention to provide T cells expressing the TCR. Another object of the present invention is to provide a preparation method of the T cell and an application of the corresponding T cell in the adoptive immune therapy of lung cancer. Another objective of the invention is to provide a computational method for predicting the binding capacity of TCR, MHC and small peptide fragments. It is another object of the present invention to provide a method for predicting a novel tumor antigen. It is still another object of the present invention to provide a method for screening T cell TCR of lung cancer tumor tissue or novel tumor antigen.

The technical scheme of the invention is as follows:

a TCR whose amino acid sequence of CDR3 of the α chain and amino acid sequence of CDR3 of the β chain are the amino acid sequences of CDR3 of the α chain and CDR3 of the β chain, respectively, or substantially similar sequences, of each of the TCRs listed in tables 1-14.

Preferably, the VJ of the α chain and VDJ of the β chain of the TCR are as listed in each of tables 1-14 for the VJ of the α chain and VDJ of the β chain of the corresponding TCR, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are as set out in each of tables 1 to 14 for the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR, respectively, or substantially similar sequences thereto.

Preferably the full length nucleic acid sequence of the α chain and the full length nucleic acid sequence of the β chain of the TCR are as set out in each of tables 1 to 14 for the corresponding TCR, or substantially homologous thereto, respectively.

The method comprises the following specific steps:

a TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.1 and SEQ ID No.3, respectively, of table 1, or sequences substantially similar thereto.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 1, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.2 and SEQ ID No.4, respectively, of Table 1, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.5 and SEQ ID No.7, respectively, or sequences substantially similar thereto, of table 2.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 2, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.6 and SEQ ID No.8, respectively, of Table 2, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.9 and SEQ ID No.11, respectively, of table 3, or sequences substantially similar thereto.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 3, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.10 and SEQ ID No.12, respectively, of Table 3, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.13 and SEQ ID No.15, respectively, or sequences substantially similar thereto, of table 4.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 4, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.14 and SEQ ID No.16, respectively, of Table 4, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.17 and SEQ ID No.19, respectively, or sequences substantially similar thereto, of table 5.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 5, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.18 and SEQ ID No.20, respectively, of Table 5, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.21 and SEQ ID No.23, respectively, or sequences substantially similar thereto, of table 6.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 6, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.22 and SEQ ID No.24 respectively of Table 6, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.25 and SEQ ID No.27, respectively, or sequences substantially similar thereto, of table 7.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 7, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.26 and SEQ ID No.28, respectively, of Table 7, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.29 and SEQ ID No.31, respectively, of table 8, or sequences substantially similar thereto.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 8, respectively.

Preferably the amino acid sequences of the V region of the α chain and the V region of the β chain of the TCR are SEQ ID No.30 and SEQ ID No.32, respectively, or sequences substantially similar thereto, of table 8.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.33 and SEQ ID No.35, respectively, or sequences substantially similar thereto, of table 9.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 9, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.34 and SEQ ID No.36, respectively, of Table 9, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.37 and SEQ ID No.39, respectively, or sequences substantially similar thereto, of table 10.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 10, respectively.

Preferably the amino acid sequences of the V region of the α chain and the V region of the β chain of the TCR are SEQ ID No.38 and SEQ ID No.40, respectively, of table 10, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.41 and SEQ ID No.43, respectively, or sequences substantially similar thereto, of table 11.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 11, respectively.

Preferably the amino acid sequences of the V region of the α chain and the V region of the β chain of the TCR are SEQ ID No.42 and SEQ ID No.44, respectively, of table 11, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.45 and SEQ ID No.47, respectively, or sequences substantially similar thereto, of table 12.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 12, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.46 and SEQ ID No.48, respectively, of Table 12, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.49 and SEQ ID No.51, respectively, or sequences substantially similar thereto, of table 13.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as correspondingly set out in table 13, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.50 and SEQ ID No.52, respectively, of Table 13, or sequences substantially similar thereto.

A TCR whose amino acid sequences of CDR3 of the α chain and CDR3 of the β chain are SEQ ID No.53 and SEQ ID No.55, respectively, or sequences substantially similar thereto, of table 14.

Preferably, VJ of the α chain and VDJ of the β chain of the TCR are as described in table 14, respectively.

Preferably the amino acid sequence of the V region of the α chain and the amino acid sequence of the V region of the β chain of the TCR are SEQ ID No.54 and SEQ ID No.56, respectively, of Table 14, or sequences substantially similar thereto.

An isolated nucleic acid encoding the amino acid sequence of CDR3 of the α chain of the above TCR, or the amino acid sequence of CDR3 of the β chain, or the amino acid sequence of the V region of the α chain, or the amino acid sequence of the V region of the β chain, or VJ of the α chain, or VDJ of the β chain, or an amino acid sequence substantially similar to said amino acid sequence.

An isolated nucleic acid encoding the full length nucleic acid sequence of the alpha chain of any one of the TCRs as set forth in tables 1-14, or the full length nucleic acid sequence of the beta chain of any one of the TCRs, or a nucleic acid sequence substantially homologous thereto.

An expression vector comprising said nucleic acid.

According to the present invention, the vector includes, but is not limited to, viruses, plasmids, cosmids, phages, yeasts, and the like.

A host cell comprising said nucleic acid.

According to the present invention, the host cell includes, but is not limited to, a eukaryotic cell, a bacterial cell, an insect cell, or a human cell. For example: vreo cells, Hela cells, COS cells, CHO cells, HEK293 cells, BHK cells, MDKII cells, Sf9 cells, and the like.

A population of T cells, T cell lines or recombinantly expressed T cells having a TCR as described above or a nucleic acid sequence encoding said TCR.

The T cell population, T cell strain, recombinantly expressed T cells, or nucleic acid sequences encoding the TCR are useful in diagnosis or therapy. For diagnosis, lung cancer can be found, or a pathological condition or prognosis can be predicted, by examining whether the above sequence is found only in a patient with lung cancer, whether the above sequence is more observed in a patient with lung cancer, or whether the above sequence accumulates in a cancer tissue of a patient with lung cancer. For the treatment of lung cancer, a T cell population, T cell strain, or recombinantly expressed T cells having the above-described TCR may be utilized.

The TCR, the isolated nucleic acid, the expression vector, the T cell population, the T cell strain or the recombinant expressed T cell are applied to preparing the medicine for treating the lung cancer.

A method of making a T cell comprising the TCR.

In one embodiment of the present invention, the preparation method may include the steps of: (1) determining the amino acid sequences of the candidate HLA and the test peptide based on the TCR of the invention; (2) synthesizing the determined HLA and the test peptide and forming a complex in vitro; (3) lymphocytes were stimulated with the HLA-peptide.

According to the present invention, the determination of the amino acid sequences of the candidate HLA-peptides can be performed based on the scores calculated using the HLA-binding peptide prediction algorithm. The candidate HLA-peptide can be determined, for example, using BIMAS, SYFPEITHI, RANKPEP, NetMHC or the like.

In another embodiment of the present invention, the preparation method may include the steps of: (1) introducing a TCR α or TCR β gene of the invention into a retroviral vector for gene expression; (2) creating a gene-introduced virus from a retroviral vector expressing TCR α and TCR β genes; (3) separately and sequentially infecting lymphocytes collected from a patient with the virus carrying the TCR α and TCR β genes to perform transfection, or creating a gene expression retroviral vector including the TCR α and TCR β genes to transform both genes at once; (4) it was demonstrated that the TCR α/TCR β heterodimer was expressed on the cell surface.

A method for single cell transcriptome TCR analysis of T cells in lung cancer tumor tissue, the method comprising the steps of: (1) obtaining individual T cells; (2) constructing a cDNA library of each T cell and sequencing to obtain the expression quantity of each gene of each cell; (3) TCR sequences and clonal recognition of individual T cells were identified.

According to the present invention, individual T cells can be obtained using a variety of methods known in the art, for example, density gradient centrifugation can be used for individual T cells in blood; for individual T cells in the tissue, milling may be used.

According to the present invention, various methods known in the art for constructing cDNA libraries of transcriptomes of single cells can be used to construct cDNA libraries of each T cell and sequence the cDNA libraries to obtain the expression level of each gene of each cell, for example: tom Rich is created in 2009 (Tang, F.et al. RNA-Seq analysis to capture the transformed Cell of Nat. Protic.5, 516-535 (2010)), STRT-Seq (single-Cell tagged reverse transcription sequencing), Smart-Seq and Smart-Seq2, Cell-Seq (Cell decompression by linear amplification and sequencing), PMA-Seq (Phi 29-mRNLighting identification and sequencing), and the like.

In a preferred embodiment of the present invention, a cDNA library of each T cell is constructed using Smart-Seq2 and sequenced to obtain the expression level of each gene of each cell.

The inventor of the invention relatively researches a method established in 2009 for soup remuneration and Smart-Seq2, and finds that the Smart-Seq2 method can detect more genes under the condition of ensuring the sequencing quality, wherein the genes comprise a marker CD3 gene shared by T lymphocytes; and the Smart-seq2 method is more beneficial to amplifying complete cDNA and is more suitable for T cell single cell transcriptome amplification.

Through experimental research, the inventor of the invention further improves the operating conditions in Smart-seq2, and improves the reverse transcription yield of mRNA and the purification efficiency of products after PCR amplification.

In the embodiment of the invention, when the Smart-seq2 method is used for reverse transcription, the following reverse transcription conditions are adopted, so that the yield of reverse transcription cDNA and the proportion of the whole length of the cDNA are improved:

compared with the common reverse transcription condition of 30 minutes at 50 ℃, the improved reverse transcription condition can improve the cDNA yield by 16-23 percent and the average length of the whole cDNA length by about 20 percent.

In the specific implementation mode of the invention, the method for purifying the PCR amplification product by adopting the Smart-seq2 method is as follows, improves the purity of the PCR product, and is beneficial to the improvement of the subsequent sequencing and library construction quality: and (3) carrying out purification twice by using magnetic beads, wherein the volume of the added magnetic beads is the same as that of the PCR amplification product during the first purification, and the volume of the added magnetic beads is 2 times of that of the PCR amplification product during the second purification.

According to the present invention, when the analysis of step (3) is performed, the biological information data obtained in step (2) is compared and quality-controlled, removing the low-quality part.

According to the invention, the method for controlling the data quality of sequencing reads (reads) of cDNA comprises the following steps: sequencing reads that met the following conditions were retained: the unknown base accounts for no more than 10% of the total sequence of the given read, the base with the Phred mass value lower than 5 does not exceed 50%, and the sequence does not contain a linker.

According to the invention, the cell quality control method is to remove cells with low data quantity and data quality and keep the cells meeting the following conditions: the TPM of CD3D is larger than 3; ② when separating CD4⁺For T cells, the TPM of CD4 needs to be more than 3, and the TPM of CD8 needs to be less than 30; ③ separating CD8⁺For T cells, the TPM of CD8 needs to be greater than 3, while the TPM of CD4 is less than 30; (iv) the ratio of reads on the mitochondrial gene to all reads is not higher than 10%. Wherein, the definition of TPM value is:

wherein C is_ijExpressed as the number of reads of gene i in cell j.

According to the present invention, the quality control method of the gene expression level of a single cell for analysis comprises: the average number of reads detected for a gene in all cells was greater than 1 before use in subsequent analyses.

According to the invention, in step (3) the TCR sequence recognition of the individual T cells is carried out using the software TraCeR.

According to the present invention, in the clonality identification in step (3), the following method is employed: comparing sequences of TCR a and TCR β in any two cells, and when at least one TCR a and at least one TCR β sequence in the two cells are completely identical, the identical sequences of TCR a and TCR β are translated into effective proteins, a TMP value of TCR a is at least greater than 10, and a TMP value of TCR β is at least greater than 15, such two cells are considered to be from the same clone.

A computational method for predicting the binding capacity of T cells in tumor tissue of a patient with lung cancer to TCR, MHC and small peptide fragments, comprising the steps of:

1) obtaining the RNA sequence of TCR of tumor immune cells of a lung cancer patient, MHC class of the tumor patient and the sequence of small peptide segment, and inputting the sequences into RosettaDock software;

2) performing homologous modeling of the protein structure on the TCR sequence according to a database of known sequences and protein structures;

3) confirming 6 loop regions (annular regions) of CDR in TCR, carrying out step-by-step simulation, and calculating the binding free energy of the 6 loop regions; the confirmation method of the 6 loop regions comprises the steps of calculating the three-dimensional structure center of the small peptide segment according to the amino acid residues of the small peptide segment, identifying the loop regions of the CDR of the TCR according to RosettaDock software, calculating the distance between each loop region and the three-dimensional structure center of the small peptide segment, and selecting the 6 loop regions with the closest distance;

4) combining MHC, TCR and small peptide segments together, and respectively carrying out butt joint process calculation with low resolution and high resolution to reach the maximum iteration times and terminate the calculation;

5) the results of the analysis, RMSD, were calculated as docking free energy and as a scoring function value (Rosetta score) indicating the strength of binding capacity.

According to the present invention, in step 1), the RNA sequence of TCR of tumor immune cells of lung cancer patients can be derived from RNA sequences of TCR disclosed in various public databases, or obtained by sequencing the tumor immune cells of lung cancer patients by various sequencing methods known in the art. Preferably, the single-cell sequencing and analysis of tumor immune cells collected from lung cancer patients are performed by using the single-cell transcriptome TCR analysis method of T cells provided by the invention, and a large number of potentially available RNA sequences of TCR are obtained for the calculation and prediction analysis of the invention.

According to the invention, in step 1), the MHC class of the patient can be obtained by applying exonic sequencing methods known in the art and running optitype, for example, see Szolek A1, Schubert B2, Mohr C2, Sturm M1, Feldhahahan M1, Kohlbacher O1.Optitype: precision HLA type from new-generating genetic information data 2014information Dec 1; 30(23) 3310-6.doi:10.1093/bioinformatics/btu548.Epub 2014Aug 20. experiments and analyses were carried out by the methods described.

According to the present invention, in step 1), the small peptide fragment sequence can be predicted in a patient using NetMHC and RNA sequencing techniques known in the art, for example, with reference to Andreatta M, Nielsen M.gapped sequence alignment using an anatomical neural network, application to the MHC class analysis.Bioinformatics (2016) Feb 15; 511-7 parts of (32); experiments and analyses were performed by the methods described in Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, Brunak S, Lund O.replaceable prediction of T-cell epitopes using neural networks with novel sequence prediction. protein Sci., (2003)12: 1007-17.

According to the present invention, the homology modeling in step 2) can be performed by translating the RNA sequence of the obtained TCR into an amino acid sequence by various homology modeling methods commonly used in the art, and predicting the three-dimensional structure of the TCR by searching for homologous proteins according to a database of known sequences and protein structures.

According to the invention, in step 3), the three-dimensional structure center of the small peptide segment is calculated according to the amino acid residues of the small peptide segment, the loop regions of the CDR of the TCR are identified according to RosettaDock software, the distance between each loop region and the three-dimensional structure center of the small peptide segment is calculated, and the 6 loop regions with the nearest distance are selected as the basis for the subsequent analysis of the binding capacity of the TCR, the MHC and the small peptide segment.

The three-dimensional structure center of the small peptide segment refers to the mean midpoint of the three-dimensional coordinates of all atoms of the small peptide. The calculation of the three-dimensional structural center of the small peptide fragment and methods thereof are known in the art.

According to the invention, in step 3), all 6 loop regions can be released during step-by-step simulation; in order to reduce the interference of the variable domain to the calculation result, only 5, 4, 3, 2 or 1 of the 6 loop regions can be released in each simulation, the rest 1, 2, 3, 4 or 5 are correspondingly fixed, and the like, and the binding free energy of each loop region is calculated. Preferably, only 1 of the 6 loop regions is released per simulation, the remaining 5 are fixed, and so on, and the binding free energy of each loop region is calculated.

According to the invention, in step 4), firstly, the conformational space obtained by homologous modeling is explored through low-resolution search, and then all atoms are locally refined through a Monte Carlo minimization algorithm. In low resolution docking, the protein is represented as a backbone plus a centroid representation of the side chains, i.e., the side chains are represented as one large atom, to save CPU time. At this stage RosettaDock attempts to find the approximate direction of the docking object for high resolution search. When high resolution docking (local refinement) is performed, all atoms in the protein are represented and the positions found in the low resolution search are also optimized. The high resolution phase consumes the most CPU time of RosettaDock.

According to the present invention, the most likely new antigen to elicit an immune response in the patient can be predicted from the scoring function obtained in step 5). The lower conformation of Rosetta score represents the lower energy state, the more likely the TCR-MHC-small peptide fragment structure with lower energy state is to be the binding conformation that is actually present in the organism, and thus the smaller peptide fragments involved in forming this conformation are the more likely the small peptides that are most likely to bind to the TCR, i.e. the more likely the new antigen that elicits the immune response, and the more likely the corresponding TCR sequence is to be the most binding TCR, which can be used for TCR-T therapy.

Thus, the computational methods can also be used to predict or screen for new lung cancer tumor antigens, and/or to predict or screen for TCR sequences that can be used for future development, improving the efficiency of obtaining TCRs with potential bioactive value from a large number of lung cancer tumor immune cell TCR sequences obtained from high throughput sequencing technologies.

To assess structural diversity within the TCR docking benchmark, the inventors compared stem conformation and more regions of the cyclic flexible structure in the TCR/pMHC structure. The superposition of the binding TCR CDR loops shows a large structural variation, especially between the CDR3 α and CDR3 β loops of the TCR, with a smaller degree of structural variation of the CDR1 α and CDR2 α loops. Within the overlap of pMHCs, peptide bone architecture appears to show great diversity, driven by different peptide sequences and lengths as well as MHC alleles and binding TCRs. The inventor selects 6 regions with the nearest distance from the region (loop region) with the large CDR structure variation degree according to the distance from the three-dimensional structure center of the small peptide fragment, and respectively carries out unconstrained dynamic adjustment on the 6 loop regions in the docking process, thereby achieving the most suitable docking result between TCR/pMHC compounds. In addition to analyzing changes between TCR/pMHC complexes in the baseline, the inventors also calculated the binding conformational changes of TCRs (both unconstrained and bound TCR structures calculated from each test case) as a function of position, and found that the CDR3 α loop exhibited the greatest average conformational change upon binding, followed by CDR3 β and CDR1 α, with less pronounced conformational changes in the other CDRs and pMHC binding sites. Therefore, the method for determining the loop region for calculation is effective and feasible, and the determination of 6 loop regions of the CDR of the TCR is enough for accurate and quick calculation.

Because the production, crystallization and structural determination of TCR-pMHC complexes are challenging, it is of great interest to model new complexes. The present inventors have taken advantage of conserved structural features in known complexes, such as restricted TCR binding sites and generally conserved diagonal docking patterns, to provide the aforementioned rapid TCR-pMHC modeling approach.

A method of screening for a TCR of a T cell in a lung cancer tumor tissue or a tumor neoantigen of lung cancer, the method comprising the steps of: 1) carrying out single cell transcriptome TCR analysis on T cells in lung cancer tumor tissues, and identifying to obtain TCR series and clonality identification of single T cells; 2) inputting the TCR obtained in the step 1), the MHC type of the tumor patient and the small peptide fragment sequence into RosettaDock software, and calculating the binding capacity of the TCR, the MHC and the small peptide fragment.

According to the invention, said step 1) further comprises the steps of: (a) obtaining individual T cells; (b) constructing a cDNA library of each T cell and sequencing to obtain the expression quantity of each gene of each cell; (c) TCR sequences and clonal recognition of individual T cells were identified.

According to the present invention, individual T cells can be obtained using a variety of methods known in the art, for example, density gradient centrifugation can be used for individual T cells in blood; for individual T cells in the tissue, milling may be used.

According to the present invention, various methods known in the art for constructing a cDNA library of a transcriptome of a single cell can be used to construct a cDNA library of each T cell and sequence the cDNA library to obtain an expression level of each gene of each cell. In a preferred embodiment of the present invention, a cDNA library of each T cell is constructed using Smart-Seq2 and sequenced to obtain the expression level of each gene of each cell.

According to the present invention, in performing the analysis of step (c), the bioinformatic data obtained in step (b) is subjected to comparison and quality control, eliminating low-quality parts.

According to the invention, the method for controlling the data quality of sequencing reads (reads) of cDNA comprises the following steps: sequencing reads that met the following conditions were retained: the unknown base accounts for no more than 10% of the total sequence of the given read, the base with the Phred mass value lower than 5 does not exceed 50%, and the sequence does not contain a linker.

According to the present invention, the cell quality control is performed by removing the number of cellsCells with low data volume and data quality, cells that meet the following conditions were retained: the TPM of CD3D is larger than 3; ② when separating CD4⁺For T cells, the TPM of CD4 needs to be more than 3, and the TPM of CD8 needs to be less than 30; ③ separating CD8⁺For T cells, the TPM of CD8 needs to be greater than 3, while the TPM of CD4 is less than 30; (iv) the ratio of reads on the mitochondrial gene to all reads is not higher than 10%. Wherein, the definition of TPM value is:

wherein C is_ijExpressed as the number of reads of gene i in cell j.

According to the present invention, the quality control method of the gene expression level of a single cell for analysis comprises: the average number of reads detected for a gene in all cells was greater than 1 before use in subsequent analyses.

According to the invention, in step (c) the TCR sequence recognition of the individual T cells is carried out using the software TraCeR.

According to the present invention, in the clonality identification of step (c), the following method is employed: comparing sequences of TCR a and TCR β in any two cells, and when at least one TCR a and at least one TCR β sequence in the two cells are completely identical, the identical sequences of TCR a and TCR β are translated into effective proteins, a TMP value of TCR a is at least greater than 10, and a TMP value of TCR β is at least greater than 15, such two cells are considered to be from the same clone.

According to the invention, step 2) further comprises the steps of: a) performing homologous modeling of protein structure on the TCR sequence according to a database of known sequences and protein structures; b) calculating the three-dimensional structure center of the small peptide segment according to the amino acid residue of the small peptide segment, identifying the loop region of the CDR of the TCR according to RosettaDock software, calculating the distance between each loop region and the three-dimensional structure center of the small peptide segment, selecting 6 loop regions with the nearest distance, performing step-by-step simulation, and calculating the binding free energy of the 6 loop regions; c) combining MHC, TCR and small peptide segments together, and respectively carrying out low-resolution and high-resolution docking process calculation to reach the maximum iteration times and terminate the calculation; d) the results of the analysis, RMSD, were calculated as the docking free energy and as a scoring function value (Rosetta score) indicating the strength of the binding capacity.

According to the present invention, the MHC class of a patient can be obtained by sequencing exons and running optitype, which are known in the art. The small peptide fragment sequence can be predicted in a patient using NetMHC and RNA sequencing techniques known in the art.

According to the present invention, the homology modeling in step a) can be performed by translating the RNA sequence of the obtained TCR into an amino acid sequence using various homology modeling methods commonly used in the art, and predicting the three-dimensional structure of the TCR by searching for homologous proteins according to a database of known sequences and protein structures.

According to the invention, in step b), all 6 loop regions can be released during step-by-step simulation; in order to reduce the interference of the variable domain to the calculation result, only 5, 4, 3, 2 or 1 of the 6 loop regions can be released in each simulation, the rest 1, 2, 3, 4 or 5 are correspondingly fixed, and the like, and the binding free energy of each loop region is calculated. Preferably, only 1 of the 6 loop regions is released per simulation, the remaining 5 are fixed, and so on, and the binding free energy of each loop region is calculated.

According to the invention, in step c) the conformational space obtained by homology modeling is first explored by low resolution search, and then all atoms are locally refined by means of a monte carlo minimization algorithm. In low resolution docking, the protein is represented as a backbone plus a centroid representation of the side chains, i.e., the side chains are represented as one large atom, to save CPU time. At this stage RosettaDock attempts to find the approximate direction of the docking object for high resolution search. When high resolution docking (local refinement) is performed, all atoms in the protein are represented and the positions found in the low resolution search are also optimized. The high resolution phase consumes the most CPU time of RosettaDock.

According to the invention, the scoring function obtained in step d) can be used to predict the most likely new antigen in the patient to elicit an immune response. The lower conformation of Rosetta score represents the lower energy state, the more likely the TCR-MHC-small peptide fragment structure with lower energy state is to be the binding conformation that is actually present in the organism, and thus the smaller peptide fragments involved in forming this conformation are the more likely the small peptides that are most likely to bind to the TCR, i.e. the more likely the new antigen that elicits the immune response, and the more likely the corresponding TCR sequence is to be the most binding TCR, which can be used for TCR-T therapy.

The novel antigen or TCR thus selected can be used to prepare T cells containing the TCR and to use the cells in the treatment of lung cancer.

For example, in one embodiment of the present invention, the method for preparing the T cell may comprise the steps of: (1) selecting the lowest TCR, MHC and small peptide sequences of Rosetta score; (2) synthesizing the identified MHC and small peptide and forming a complex in vitro; (3) lymphocytes were stimulated with the MHC-small peptide.

In another embodiment of the present invention, the method for preparing the T cell may include the steps of: (1) selecting the lowest TCR, MHC and small peptide sequences of Rosetta score; introducing the TCR α or TCR β gene into a retroviral vector for gene expression; (2) creating a gene-introduced virus from a retroviral vector expressing TCR α and TCR β genes; (3) separately and sequentially infecting lymphocytes collected from a patient with the virus carrying the TCR α and TCR β genes to perform transfection, or creating a gene-expressing retroviral vector including the TCR α and TCR β genes to transform both genes at once; (4) it was demonstrated that the TCR α/TCR β heterodimer was expressed on the cell surface.

In the present invention:

"homologous," when used to describe nucleic acids, means that at least 80% of the nucleotides, and more preferably at least about 98% to 99% of the nucleotides, are identical, with appropriate nucleotide insertions or deletions, when the two nucleic acids or their designated sequences are aligned and compared in the optimal alignment. The term "homologue" or "homologous" also refers to homology in terms of structure and/or function. In terms of sequence homology, if a plurality of sequences are at least 80% identical or more, for example: at least 90%, at least 95%, at least 97% or at least 99%, they are homologs. The term "substantially homologous" refers to a sequence that is at least 90% identical or greater, e.g., at least 95% identical, at least 97% identical, or at least 99% identical.

The term "substantial similarity", when used in reference to a polypeptide sequence, indicates that such polypeptide comprises a sequence that is at least 80% identical, or most preferably 90% identical, or most preferably 95% identical, or most preferably 99% identical to the reference sequence over a comparison window of about 10-100 amino acid residues (e.g., the variable region of the heavy or light chain of an antibody, the V region of the α or β chain of a TCR). In the context of amino acid sequences, "substantial similarity" further includes conservative substitutions of amino acids. The term "substantial identity" means that two peptide sequences, when optimally aligned (e.g., by the programs GAP or BESTFIT using default GAP weights), share at least 80% sequence identity, preferably at least 90% sequence identity, more preferably at least 95% or more sequence identity (e.g., at least 99% or more sequence identity). Preferably, residue positions that are not identical differ by conservative amino acid substitutions.

The determination of homologues of the gene or amino acid sequences of the present invention can be readily determined by the skilled person.

The terms "malignancy," "tumor," and "cancer" are used interchangeably to refer to a disease or disorder characterized by uncontrolled, hyperproliferative or abnormal growth or metastasis of cells.

In the present invention, unless otherwise specified, the amino acid sequence is from the N-terminus to the C-terminus, and the base sequence is from the 5 '-terminus to the 3' -terminus.

Drawings

FIG. 1 flow sorting of single cells. Longitudinal direction: first row: t cells in peripheral blood; a second row: t cells in normal tissue; third row: t cells in tumor tissue. Transverse: first column: selecting live cells; the second column: selection of CD3 in live cells⁺Samples (T cells); third column: in CD3⁺Selection of CD4 in cells⁺And CD8⁺A cell; fourth column: in CD4⁺The strong positive CD25 is selected from the cells,CD25 weakly positive and CD25 negative cells.

FIG. 2 is a graph showing the results of Fragment Analysis assay of qualified single-cell cDNA library.

FIG. 3 is a flow chart of TCR/pMHC docking simulation using RosettaDock.

Detailed Description

The present invention is further described below with reference to examples.

The following example is an illustration of a method for analyzing single cell T cell transcriptome in lung cancer patients.

It should be noted that the examples are not intended to limit the scope of the present invention, and those skilled in the art will appreciate that any modifications and variations based on the present invention are within the scope of the present invention.

The chemical reagents used in the following examples are conventional and are commercially available.

The analytical software used and its source were as follows:

GSNAP(http://research-pub.gene.com/gmap/)；

TraCeR(https://github.com/Teichlab/tracer)；

statistical software R (https:// www.r-project. org /).